Pain assessment is fundamental to medicine, with 90% of patients citing pain as their primary complaint. Yet, current evaluation methods rely entirely on verbal self-reporting, creating a critical healthcare gap for non-verbal patients such as babies, individuals with autism, Down syndrome, Alzheimer, cerebral palsy, and those with other conditions affecting communication.  Recent studies published in the The Lancet confirms that these patients face a 30% higher risk of misdiagnosis and inadequate treatment, often with fatal consequences with increasing mortality rates. This invisible suffering represents a global healthcare crisis affecting millions. The same research outlined the necessity of developing new medical tools to measure pain and treat it based on technology like AI, whose accuracy and objectivity could positively impact pain treatment for millions of non-verbal patients worldwide.  For GSK, a pharmaceutical leader committed to improving quality of life through science, PainVisible aligns perfectly with their mission to deliver transformative healthcare solutions. As pain management constitutes a significant portion of GSK's portfolio, the company recognized the urgent need for objective pain assessment tools.  PainVisible was developed in Brazil, and tested in hospitals in Miami, Brazil and across Spain. The solution comes at a crucial moment when healthcare systems worldwide are seeking AI-powered innovations to address longstanding medical challenges and reduce healthcare disparities.  Furthermore, PainVisible could potentially help millions of patients in the USA, where pain is both under- and over-treated, leading to thousands of deaths from overdoses (OD) each year.